Pharma: Page 2


  • The outside of an AbbVie building, with the company's logo displayed.
    Image attribution tooltip
    AbbVie
    Image attribution tooltip

    AbbVie weathers first months of biosimilar challenge to top-selling Humira

    While Humira sales declined, the drop was mostly due to price concessions AbbVie made to secure equal insurer access in the face of copycat competition.

    By April 28, 2023
  • Obesity drugs

    Lilly plans dash to market for weight loss drug after trial win

    The drugmaker will use a priority review voucher in a bid to secure FDA approval of Mounjaro in obesity by late this year or early next.

    By April 27, 2023
  • Single strand ribonucleic acid, RNA research Explore the Trendline
    Image attribution tooltip
    luismmolina via Getty Images
    Image attribution tooltip
    Trendline

    The expanding world of RNA therapies

    Vaccines from BioNTech and Moderna proved the power of messenger RNA in medicine. A growing field of RNA-targeting therapies is advancing alongside them.

    By BioPharma Dive staff
  • A box of Eli Lilly's diabetes drug Mounjaro is held for a photo.
    Image attribution tooltip

    George Frey/Reuters

    Image attribution tooltip
    Obesity drugs

    Lilly drug Mounjaro succeeds in second weight loss study

    Trial participants nearly 16% of their body weight in a finding that should help the closely watched GLP-1 drug gain an FDA approval for obesity.

    By April 27, 2023
  • Giovanni Caforio, chairman of the board and CEO of Bristol-Myers Squibb Co., testifies before the Senate Finance Committee on "Drug Pricing in America: A Prescription for Change, Part II" February 26,
    Image attribution tooltip
    Win McNamee via Getty Images
    Image attribution tooltip

    Bristol Myers’ Caforio stepping down as CEO in November

    Commercial chief Christopher Boerner will take over after spending the next six months as chief operating officer. Giovanni Caforio will continue to serve as chair of Bristol Myers’ board.

    By Updated April 26, 2023
  • Roche Pharmaceutical Group's office building in Shanghai, China
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Roche’s new eye drug pressures Eylea with strong launch

    One year after its market debut, the company’s AMD drug Vabysmo is on track for blockbuster sales as Regeneron’s rival treatment faces new threats.

    By April 26, 2023
  • Exterior sign of Bristol-Myers Squibb
    Image attribution tooltip
    Permission granted by Bristol-Myers Squibb
    Image attribution tooltip

    Bristol Myers boosts cell therapy production with Novartis plant

    Accessing the Illinois facility will expand Bristol Myers’ supply of viral vectors following manufacturing struggles with CAR-T drugs Abecma and Breyanzi.

    By Kristin Jensen • April 26, 2023
  • Image attribution tooltip
    Jacob Bell
    Image attribution tooltip

    Novartis trims 10% of drug pipeline in research cutback

    The company cut about 20 early-stage projects, including nine solid tumor programs, after reviewing their strategic fit and commercial potential.

    By April 25, 2023
  • Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    J&J’s consumer health spinoff seeking $3B stock offering in test of IPO market

    The planned IPO by the pharma’s consumer arm would value the new standalone company at over $40 billion.

    By April 25, 2023
  • Lilly sells emergency diabetes drug for $500M

    The divestment of Baqsimi to Amphastar could net Lilly more than $1 billion if sales goals are met.

    By April 24, 2023
  • Image attribution tooltip
    Novartis
    Image attribution tooltip

    Novartis plant cleared to produce in-demand cancer drug

    The FDA has approved the pharma, which has had difficulty producing radiopharmaceutical drugs, to make its treatment Pluvicto at a New Jersey site.

    By April 24, 2023
  • Corporate logos are seen outside  on May 15, 2006, in Macclesfield, England.
    Image attribution tooltip
    Christopher Furlong via Getty Images
    Image attribution tooltip

    Ionis, AstraZeneca detail data backing rare disease rival to Alnylam drugs

    A second-generation treatment called eplontersen halted nerve damage and improved quality of life in a late-stage study the companies are using to seek U.S. approval.

    By April 24, 2023
  • Male and female clinicians looking at laptop
    Image attribution tooltip
    Permission granted by Qiagen
    Image attribution tooltip
    Sponsored by Qiagen

    The rise of AI in pharma: make it work for you

     AI-derived data can range from insightful to useless. Learn how to get one and not the other.

    April 24, 2023
  • People sitting on the floor.
    Image attribution tooltip

    FatCamera |GettyImages-1456372164

    Image attribution tooltip
    Sponsored by Viatris

    Partnership is key to caring for multiple sclerosis patients throughout their journey

    Empowering people to live healthier goes beyond developing the right treatments.

    By Anne Berger, Head of Alliance Development, Viatris • April 24, 2023
  • Photomicrograph of a diffuse large B-cell lymphoma (DLBCL) a type of non-Hodgkin lymphoma.
    Image attribution tooltip
    iStock / Getty Images Plus via Getty Images
    Image attribution tooltip

    FDA approves earlier use of Roche’s Polivy in common form of lymphoma

    The agency’s decision also converts the biologic drug's approval from accelerated to full, confirming an earlier OK based on tumor responses.

    By April 20, 2023
  • An outside view of an Amgen building.
    Image attribution tooltip
    Amgen Inc.
    Image attribution tooltip

    Appeals court sides with Amgen in patent fight over psoriasis drug Otezla

    With the court victory, the biotech giant could stave off a set of generic competitors for the top-selling drug until 2028.

    By Kristin Jensen • April 20, 2023
  • Image attribution tooltip
    Mario Tama via Getty Images
    Image attribution tooltip

    J&J leans on cancer drug sales to maintain first quarter growth

    Revenue topped analyst forecasts on strong market performance from the pharma’s multiple myeloma treatments, as well as the last quarter of significant COVID-19 vaccine sales.

    By April 18, 2023
  • Image attribution tooltip
    Leon Neal via Getty Images
    Image attribution tooltip

    GSK to buy Bellus Health and its chronic cough drug for $2B

    The acquisition gives GSK a competitor to a similar drug being developed by Merck for the condition, which the companies estimate affects millions of people in the U.S.

    By April 18, 2023
  • Pneumococcal pneumonia, medical concept - stock photo
    Image attribution tooltip
    Dr_Microbe via Getty Images
    Image attribution tooltip

    Vaxcyte strengthens case for experimental pneumococcal vaccine

    The company reported positive results from a second Phase 2 study of a shot that’s meant to challenge vaccines from Pfizer, Merck and GSK.

    By Updated May 3, 2023
  • People working in lab
    Image attribution tooltip
    Permission granted by Cardinal Health
    Image attribution tooltip
    Sponsored by Cardinal Health

    Navigate the complexities of cell and gene therapies

    See how the effective use of CMC expertise helped guide a biopharma company’s development of a CGT product.

    April 17, 2023
  • Close-up of a sign with office building and trees in background
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    FDA again knocks back Alvotech’s Humira biosimilar

    The agency rejected the partners’ copycat version of AbbVie’s blockbuster drug for a second time, citing problems spotted during the inspection of a manufacturing facility.

    By April 14, 2023
  • Novo boosts sales outlook on strong demand for obesity drug

    The Danish drugmaker nearly doubled the 2023 forecasts for Wegovy and Ozempic in the latest indicator of the sales potential of an emerging and competitive class of weight loss drugs. 

    By Kristin Jensen • April 13, 2023
  • Exterior building picture of the Merck KGaA Life Science site in Burlington, U.S.
    Image attribution tooltip
    Courtesy of Merck KGaA
    Image attribution tooltip

    FDA, citing safety concerns, places partial hold on Merck KGaA’s MS drug

    Evidence of possible liver damage among study participants adds to growing concerns about the potential of BTK inhibitors to treat MS, a strategy being pursued by several large drugmakers. 

    By Kristin Jensen • April 12, 2023
  • An AbbVie sign is seen on the outside of a building in California.
    Image attribution tooltip
    Courtesy of AbbVie
    Image attribution tooltip

    AbbVie removes two approvals for blood cancer drug Imbruvica

    In paring back use of Imbruvica, the drugmaker has become the latest developer to voluntarily withdraw indications for a cancer medicine following a setback in confirmatory testing.

    By April 7, 2023
  • Human respiratory syncytial virus virions are shedding from the surface of human lung cells.
    Image attribution tooltip
    National Institute of Allergy and Infectious Diseases. (2017). "Human Respiratory Syncytial Virus" [Micrograph]. Retrieved from Flickr.
    Image attribution tooltip
    RSV vaccines

    In NEJM, full Pfizer data show RSV vaccine’s protection

    Shots from Pfizer and GSK could soon become the first approved for the common respiratory infection. Results published in the high-profile medical journal give a closer look at the former.

    By Updated April 6, 2023
  • A flag showing the Sartorius logo is seen in front of a manufacturing plant.
    Image attribution tooltip
    Courtesy of Sartorius
    Image attribution tooltip

    Pharma partner Sartorius eyes gene therapy market with $2.6B deal

    The biotech tools supplier is acquiring Polyplus, a French company that makes components essential to the viral vector backbones of gene therapies.

    By March 31, 2023